Immunomedics Inc Watch

EX-10.52

from 10-Q 7 pages Immunomedics, Inc. Restricted Stock Units Notice Under the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan

12/34/56

EX-10.51

from 10-Q 8 pages Immunomedics, Inc. Restricted Stock Units Notice Under the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan

12/34/56

EX-10.50

from 10-Q 8 pages Immunomedics, Inc. Nonqualified Stock Option Notice

12/34/56

EX-10.49

from 10-Q 9 pages Immunomedics, Inc. Incentive Stock Option Notice

12/34/56

EX-10.1

from 8-K 32 pages Immunomedics, Inc. Amended & Restated 2014 Long-Term Incentive Plan

12/34/56

EX-10.1

from 8-K 9 pages Certain Identified Information Has Been Excluded From This Exhibit in Accordance With Regulation S-K Item 601(a)(6) Because It Would Constitute a Clearly Unwarranted Invasion of Personal Privacy. [***] Indicates That Information Has Been Redacted. May 27, 2020 Harout Semerjian [***] [***] Re: Separation From Employment Dear Harout: This Confidential Separation Agreement and Release (“Agreement”), Sets Forth the Agreement Reached Concerning the Termination of Your Employment With Immunomedics, Inc. (The “Company”). 1. Separation Date

12/34/56

EX-10.46

from 10-Q 10 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Immunomedics, Inc. Performance-Based Restricted Stock Units Notice Under the Immunomedics, Inc. 2014 Long-Term Incentive Plan

12/34/56

EX-10.45

from 10-Q 10 pages Immunomedics, Inc. Restricted Stock Units Notice Under the Immunomedics, Inc. 2014 Long-Term Incentive Plan

12/34/56

EX-10.44

from 10-Q 11 pages Immunomedics, Inc. Non Qualified Stock Option Notice

12/34/56

EX-10.43

from 10-Q 17 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Executive Employment Agreement

12/34/56

EX-10.42

from 10-Q 11 pages Immunomedics, Inc. Incentive Stock Option Notice

12/34/56

EX-10.41

from 10-Q 21 pages Executive Employment Agreement

12/34/56

EX-10.9

from 10-K 81 pages Lease Agreement Between Wu/Lh 400 American L.L.C., as Landlord -And- Immunomedics, Inc., as Tenant Table of Content

12/34/56

EX-10.3

from 10-Q 10 pages Consulting Agreement

12/34/56

EX-10.2

from 10-Q 73 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted

12/34/56

EX-10.1

from 10-Q 66 pages Promotion Agreement by and Between Janssen Biotech, Inc. and Immunomedics, Inc. Dated as Of: April 5, 2019

12/34/56

EX-10.3

from 10-Q 13 pages Executive Employment Agreement

12/34/56

EX-10.2

from 10-Q 6 pages March 13, 2019 Michael Pehl Re: Separation From Employment Dear Michael: This Confidential Separation Agreement and Release (“Agreement”) Sets Forth the Agreement Reached Concerning the Termination of Your Employment With Immunomedics, Inc. (The “Company”). 1. Separation Date. (A)you Acknowledge That, by Letter Dated February 22, 2019, You Resigned From Your Positions as Chief Executive Officer and President of the Company and Resigned From the Board of Directors of the Company, Which Resignations Were Accepted by the Company and Effective as of February 23, 2019

12/34/56

EX-10.1

from 10-Q 1 page March 7, 2019 Dear Scott,

12/34/56

EX-10.66

from 10-KT ~50 pages Confidential Treatment Has Been Requested With Respect to Portions of This Agreement as Indicated by “[***]” and Such Confidential Portions Have Been Deleted and Filed Separately With the Securities and Exchange Commission Pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as Amended. Manufacturing Service Agreement

12/34/56